WHEN IT COMES TO DIABETES DRUGS, there’s just something about Toronto researchers. In 1984, 63 years after Banting and Best isolated insulin, Daniel Drucker, another U of T alumnus, co-discovered glucagon-like peptide-1, or GLP-1, a gut hormone that lowers blood sugar and suppresses appetite. Drucker and Co.’s eureka moment was exciting-ish in endocrinology circles. But it wasn’t until decades later, when a GLP-1-mimicking drug called semaglutide proved effective for weight loss, that their work became the shot taken ’round the world.
The ripples of the “Ozempic effect” are now unfathomably huge: a suite of evermore GLP-1 drugs (Wegovy, Mounjaro and Rybelsus), a soon-to-be $100-billion industry, so many op-eds about our screwed-up body politics, witch hunts around celebrity users and, on a more serious note, widespread shortages that are expected to last…
